A phase 3 trial of Deciphera’s ripretinib in gastrointestinal stromal tumors has hit its primary endpoint. The data sparked a surge in the company's stock price, even though details of the results leave scope to question ripretinib’s prospects.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,